Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: A matter of undetermined significance

G. V. Manson, E. Campagnaro, A. Balog, D. Kaplan, S. R. Sommers, P. Fu, S Vincent Rajkumar, H. M. Lazarus

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition secondary MGUS (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/ immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000-2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as abnormal protein banding, we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (P0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months, P0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.

Original languageEnglish (US)
Pages (from-to)1212-1216
Number of pages5
JournalBone Marrow Transplantation
Volume47
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Cell Transplantation
Hematopoietic Stem Cells
Multiple Myeloma
Electrophoresis
Cohort Studies
Paraproteinemias
Anniversaries and Special Events
North America
Plasma Cells
Blood Proteins
Proteins
Control Groups

Keywords

  • autologous hematopoietic progenitor cell transplant
  • monoclonal gammopathy of undetermined significance
  • plasma cell myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma : A matter of undetermined significance. / Manson, G. V.; Campagnaro, E.; Balog, A.; Kaplan, D.; Sommers, S. R.; Fu, P.; Rajkumar, S Vincent; Lazarus, H. M.

In: Bone Marrow Transplantation, Vol. 47, No. 9, 09.2012, p. 1212-1216.

Research output: Contribution to journalArticle

Manson, G. V. ; Campagnaro, E. ; Balog, A. ; Kaplan, D. ; Sommers, S. R. ; Fu, P. ; Rajkumar, S Vincent ; Lazarus, H. M. / Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma : A matter of undetermined significance. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 9. pp. 1212-1216.
@article{df40821e64074662bbdfd3a652681138,
title = "Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: A matter of undetermined significance",
abstract = "Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition secondary MGUS (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/ immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000-2009. In all, 22 of 92 patients (24{\%}) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as abnormal protein banding, we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (P0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months, P0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.",
keywords = "autologous hematopoietic progenitor cell transplant, monoclonal gammopathy of undetermined significance, plasma cell myeloma",
author = "Manson, {G. V.} and E. Campagnaro and A. Balog and D. Kaplan and Sommers, {S. R.} and P. Fu and Rajkumar, {S Vincent} and Lazarus, {H. M.}",
year = "2012",
month = "9",
doi = "10.1038/bmt.2011.244",
language = "English (US)",
volume = "47",
pages = "1212--1216",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma

T2 - A matter of undetermined significance

AU - Manson, G. V.

AU - Campagnaro, E.

AU - Balog, A.

AU - Kaplan, D.

AU - Sommers, S. R.

AU - Fu, P.

AU - Rajkumar, S Vincent

AU - Lazarus, H. M.

PY - 2012/9

Y1 - 2012/9

N2 - Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition secondary MGUS (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/ immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000-2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as abnormal protein banding, we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (P0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months, P0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.

AB - Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition secondary MGUS (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/ immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000-2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as abnormal protein banding, we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (P0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months, P0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.

KW - autologous hematopoietic progenitor cell transplant

KW - monoclonal gammopathy of undetermined significance

KW - plasma cell myeloma

UR - http://www.scopus.com/inward/record.url?scp=84865957490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865957490&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.244

DO - 10.1038/bmt.2011.244

M3 - Article

C2 - 22158387

AN - SCOPUS:84865957490

VL - 47

SP - 1212

EP - 1216

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -